Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Bitterman

Showing results (11-20 of 66) with videos related to

Pageof 7
Sort By:
Israel Journal of Medical Sciences|April 1, 1993
Filariasis caused by Loa loa in an Israeli temporary resident of west AfricaM Ciobotaru, M Ephros, H Bitterman
Clinical Nuclear Medicine|November 1, 1993
Scintigraphic evaluation of a patient with hemangiosarcoma. Labeled red blood cell imaging is nondiagnosticR Hardoff, E Aghai, H Bitterman
The New England Journal of Medicine|January 2, 1992
Medical problems associated with underwater divingY Melamed, A Shupak, H Bitterman
Shock (Augusta, Ga.)|January 9, 1998
The effect of nitric oxide synthase inhibition on hypertonic saline treatment of controlled hemorrhagic shockM M Krausz, T Amstislavsky, H Bitterman
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)|July 1, 1988
Anti-shock effects of human superoxide dismutase in splanchnic artery occlusion (SAO) shockH Bitterman, N Aoki, A M Lefer
Circulatory Shock|January 1, 1987
Use of hypertonic saline in the treatment of hemorrhagic shockH Bitterman, J Triolo, A M Lefer
Circulatory Shock|January 1, 1986
Beneficial actions of thromboxane receptor antagonism in hemorrhagic shockH Bitterman, A Yanagisawa, A M Lefer
Lymphokine and Cytokine Research|October 1, 1992
Ex vivo secretion of tumor necrosis factor and interleukin-2 by rat splenocytes after intestinal ischemia and shockS Cohen, N Lahat, A Kinarty, et al.
Harefuah|May 5, 2007
[Internal medicine 2007--where do we stand? To expand or to reduce?]Y Shoenfeld, D Dicker, M Mittelman, et al.
Arzneimittel-Forschung|October 1, 1988
Use of the novel cardiotonic and vasodilator agent pimobendan in traumatic shockH Bitterman, B A Smith, A M Lefer
Pageof 7

Showing results (11-20 of 66) with videos related to

Sort By:
Pageof 7
Israel Journal of Medical Sciences|April 1, 1993
Filariasis caused by Loa loa in an Israeli temporary resident of west AfricaM Ciobotaru, M Ephros, H Bitterman
Clinical Nuclear Medicine|November 1, 1993
Scintigraphic evaluation of a patient with hemangiosarcoma. Labeled red blood cell imaging is nondiagnosticR Hardoff, E Aghai, H Bitterman
The New England Journal of Medicine|January 2, 1992
Medical problems associated with underwater divingY Melamed, A Shupak, H Bitterman
Shock (Augusta, Ga.)|January 9, 1998
The effect of nitric oxide synthase inhibition on hypertonic saline treatment of controlled hemorrhagic shockM M Krausz, T Amstislavsky, H Bitterman
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)|July 1, 1988
Anti-shock effects of human superoxide dismutase in splanchnic artery occlusion (SAO) shockH Bitterman, N Aoki, A M Lefer
Circulatory Shock|January 1, 1987
Use of hypertonic saline in the treatment of hemorrhagic shockH Bitterman, J Triolo, A M Lefer
Circulatory Shock|January 1, 1986
Beneficial actions of thromboxane receptor antagonism in hemorrhagic shockH Bitterman, A Yanagisawa, A M Lefer
Lymphokine and Cytokine Research|October 1, 1992
Ex vivo secretion of tumor necrosis factor and interleukin-2 by rat splenocytes after intestinal ischemia and shockS Cohen, N Lahat, A Kinarty, et al.
Harefuah|May 5, 2007
[Internal medicine 2007--where do we stand? To expand or to reduce?]Y Shoenfeld, D Dicker, M Mittelman, et al.
Arzneimittel-Forschung|October 1, 1988
Use of the novel cardiotonic and vasodilator agent pimobendan in traumatic shockH Bitterman, B A Smith, A M Lefer
Pageof 7